INDO US BIOTECH
Back to Balance Sheet
|
INDO US BIOTECH Last 5 Year Total Non-Current Liabilities History
[Standalone]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Total Non-Current Liabilities | ₹3.59 Cr | ₹2.09 Cr | ₹4.07 Cr | ₹3.92 Cr | ₹1.52 Cr |
What is the latest Total Non-Current Liabilities ratio of INDO US BIOTECH ?
Year | Total Non-Current Liabilities |
---|---|
Mar2024 | ₹3.59 Cr |
Mar2023 | ₹2.09 Cr |
Mar2022 | ₹4.07 Cr |
Mar2021 | ₹3.92 Cr |
Mar2020 | ₹1.52 Cr |
How is Total Non-Current Liabilities of INDO US BIOTECH Trending?
Years | Total Non-Current Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹3.59 Cr | 71.41 | |
Mar2023 | ₹2.09 Cr | -48.61 | |
Mar2022 | ₹4.07 Cr | 3.96 | |
Mar2021 | ₹3.92 Cr | 157.12 | |
Mar2020 | ₹1.52 Cr | - |
Compare Total Non-Current Liabilities of peers of INDO US BIOTECH
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
INDO US BIOTECH | ₹323.6 Cr | -1% | -18.2% | -39.7% | Stock Analytics | |
BOMBAY BURMAH TRADING CORPORATION | ₹12,333.2 Cr | 0% | 4.6% | 14.7% | Stock Analytics | |
KAVERI SEED COMPANY | ₹7,489.8 Cr | 15.2% | 43.4% | 108.6% | Stock Analytics | |
VENKYS (INDIA) | ₹2,300.1 Cr | 1.1% | -0.1% | 1.6% | Stock Analytics | |
BOMBAY SUPER HYBRID SEEDS | ₹1,298.6 Cr | 2.4% | -4.8% | -49.4% | Stock Analytics | |
MANGALAM GLOBAL ENTERPRISE | ₹452.8 Cr | -9.3% | -12.6% | NA | Stock Analytics |
INDO US BIOTECH Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
INDO US BIOTECH | -1% |
-18.2% |
-39.7% |
SENSEX | -2.9% |
3.1% |
1.8% |
You may also like the below Video Courses